---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-021990"
form_type: "8-K/A"
ticker: "TVGN"
cik: "0001860871"
company_name: "Tevogen Bio Holdings Inc."
filed_at: "2024-05-30T23:59:59+00:00"
generated_at: "2026-06-01T07:28:49.896457+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Tevogen Bio Inc reports 2023 net loss of $60.5M; cash only $1.05M, going concern raised

## Summary
- Net loss of $60.5M in 2023 ($2.44/share) vs $22.0M in 2022; no revenue.
- Operating expenses $8.8M; $50.4M non-cash loss from change in fair value of convertible notes.
- Accumulated deficit $99.7M; cash $1.05M at Dec 31, 2023.
- Auditors express substantial doubt about ability to continue as going concern.
- Post-balance sheet: $2M Series A Preferred (Feb 2024) and $1.2M Series A-1 Preferred.

## SEC filing metadata
- accession: 0001493152-24-021990
- form_type: 8-K/A
- ticker: TVGN
- cik: 0001860871
- company_name: Tevogen Bio Holdings Inc.
- filed_at: 2024-05-30T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860871/000149315224021990/0001493152-24-021990-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860871/000149315224021990/form8-ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-021990
- JSON: https://secwatch.observer/filing/0001493152-24-021990.json
- Plain text: https://secwatch.observer/filing/0001493152-24-021990.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.